Skip to content

The value of 18F-FDG PET/CT radiomics combined with clinicopathological features to predict molecular typing and Ki67 expression of breast cancer

The value of 18F-FDG PET/CT radiomics combined with clinicopathological features to predict molecular typing and Ki67 expression of breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077761
Enrollment
Unknown
Registered
2023-11-18
Start date
2023-11-18
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Pathological diagnosis

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) over 18 years of age; (2) No treatment was performed before the 18F-FDG PET/CT standard examination; (3) Histological data were obtained from puncture biopsy or surgical specimens; (4) Complete immunohistochemical and fluorescence in situ hybridization (FISH) results; (5) Complete clinical and pathological data sets (including menopausal status, tumor location, tissue type, and lymph node status, etc.) are available.

Exclusion criteria

Exclusion criteria: (1) The 18F-FDG PET/CT image is incomplete or of poor quality; (2) No abnormal increase in FDG uptake was observed in 18F-FDG PET/CT images. (3) The primary lesion is too small to be segmented; (4) A history of other cancers.

Design outcomes

Primary

MeasureTime frame
estrogen receptor,;progesterone receptor,;human epidermal growth factor receptor2;

Countries

China

Contacts

Public ContactDeng Shengming

The First Affiliated Hospital of Soochow University

dshming@163.com+86 150 5151 0189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026